US Bioservices now dispenses VERZENIO™
9/28/17 The U.S. Food and Drug Administration has approved VERZENIO™ (abemaciclib) in combination with fulvestrant for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer that has progressed after endocrine therapy. VERZENIO™ is also approved as a monotherapy for the treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. Continue reading now.
US Bioservices is supporting patients affected by Hurricane Irma
9/8/17 As Hurricane Irma prepares to make landfall, our thoughts are with those who will be impacted by the storm. Patient care is our priority, and we are here to provide care and support during this challenging time. Continue reading now.
US Bioservices is proud to support our patients with Duchenne Muscular Dystrophy
9/7/17 In honor of Duchenne Awareness Day, we stand in support with patients and caregivers affected by this rare and fatal disease. Continue reading now.
US Bioservices is supporting patients affected by Hurricane Harvey
8/30/17 Our thoughts are with all those affected by the devastating flooding and damage caused by Hurricane Harvey. US Bioservices is currently working to deliver medications to patients living along the Texas and Louisiana Gulf Coast region impacted by this storm. Continue reading now.
US Bioservices is now dispensing MAVYRET™
8/10/17 The U.S. Food and Drug Administration has approved MAVYRET™ (glecaprevir and pibrentasvir) for the treatment of patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis. It is also indicated for adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. Continue reading now.
Kelly Ratliff featured in Specialty Pharmacy Times article: "The Women of Specialty Pharmacy: Industry Advocates, Entrepreneurs, Innovators"
8/2/17 There is no doubt that female leaders have helped shape the current state of specialty pharmacy and continue to enable its growth. Many of these dynamic, influential women joined the ranks of leadership over the past 2 decades, disrupting what was once largely a male-dominated industry. Continue reading now.
US Bioservices is now dispensing VOSEVI™
7/28/17 The U.S. Food and Drug Administration has approved VOSEVI™(sofosbuvir, velpatasir, and voxilaprevir) for the re-treatment of adult patients with chronic hepatitis C (HCV) infection in adults with genotypes 1-6 previously treated with NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor. Continue reading now.
US Bioservices is now dispensing TREMYFA™
7/24/17 The U.S. Food and Drug Administration has approved TREMFYA™ (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Continue reading now.
Add Value to Your Specialty Strategy
7/20/17 The specialty market is constantly evolving: while many specialty pharmacies are consolidating, many more are emerging. The acquisition of specialty pharmacies by managed care organizations and pharmacy benefit managers is a driving force as well. Continue reading now.
US Bioservices is now dispensing RITUXAN HYCELA™
6/27/17 The U.S. Food and Drug Administration has approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with specific forms of lymphoma and leukemia. Continue reading now.
CPPA Accredits US Bioservices, a part of AmerisourceBergen, for Specialty Pharmacy
6/23/17 WASHINGTON, D.C. – The Center for Pharmacy Practice Accreditation (CPPA), a partnership of pharmacy-based organizations, announced today that it has awarded specialty pharmacy practice accreditation to US Bioservices, a specialty pharmacy and part of AmerisourceBergen. Continue reading now.
US Bioservices is now dispensing RYDAPT®
5/1/17 The U.S. Food and Drug Administration recently approved RYDAPT® (midostaurin) for the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM). Continue reading now.
US Bioservices selected by Tesaro to dispense ZEJULA™
4/19/17 US Bioservices, an independent specialty pharmacy and part of AmerisourceBergen, announced today it has been selected by TESARO, Inc. as a specialty pharmacy partner for ZEJULA™ (niraparib). Continue reading now.
US Bioservices is now dispensing OCREVUS™
3/30/17 OCREVUS™ (ocrelizumab) is a prescription medication by Genentech used to treat adults with relapsing and primary progressive forms of multiple sclerosis. Continue reading now.
US Bioservices is now dispensing DUPIXENT®
3/30/17 The U.S. Food and Drug Administration recently approved Sanofi and Regeneron’s DUPIXENT® (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Continue reading now.
US Bioservices is now dispensing Novartis’ KISQALI®
3/16/17 The U.S Food and Drug Administration recently approved Novartis’ KISQALI®(ribociclib) for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer. Continue reading now.
The Pharmaceutical Ecosystem Must Work Together to Provide Sustainable Innovation and Ensure Patient Access
3/15/17 For many patients with rare diseases, reaching the first step of an accurate diagnosis can be a lengthy journey, riddled with pain, difficulty, and trial and error—and that’s before they begin the challenge of fighting and treating their conditions. Continue reading now.
US Bioservices selected by AstraZeneca to dispense IRESSA and TAGRISSO
2/6/17 US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by AstraZeneca to dispense IRESSA® (gefitinib) and TAGRISSO® (osimertinib) for the treatment of advanced non-small cell lung cancer in patients whose tumors foster gene mutations.Continue reading now.
President Kelly Ratliff publishes article in Targeted Therapies in Oncology
2/2/17 Kelly Ratliff, DPh, shares how increased collaboration among healthcare providers helps patients taking oral oncolytics overcome barriers to therapy access and adherence. Continue reading now.
US Bioservices selected by Clovis Oncology to dispense RUBRACA
12/20/16 US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by Clovis Oncology to dispense RUBRACA® (rucaparib). Continue reading now.
US Bioservices has once-daily VIEKIRA XR® in stock
8/3/16 VIEKIRA XR® was approved by the U.S. Food and Drug Administration on July 25, 2016 as a once-daily, extended-release co-formulation of the active ingredients in VIEKIRA XR (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and is for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis (Child-Pugh A). VIEKIRA XR is not for people with decompensated cirrhosis. Continue reading now.
US Bioservices has Pfizer’s XALKORI® in stock – now FDA approved to treat metastatic non-small cell lung cancer
7/11/16 The U.S. Food and Drug Administration recently approved the expanded use of Pfizer’s XALKORI® (crizotinib) for the treatment of metastatic non-small cell lung cancer (NSCLC), when tumors have an ROS-1 gene alteration. The FDA also granted XALKORI® breakthrough therapy designation and priority review status. Continue reading now.
US Bioservices has Genentech’s XOLAIR® in stock
7/5/16 US Bioservices has been selected as an authorized specialty pharmacy in a limited distribution network for XOLAIR® (omalizumab). Xolair is an anti-IgE antibody subcutaneous injection medication with two therapeutic indications.Continue reading now.
US Bioservices Dispensing Gilead’s EPCLUSA® for All Genotypes of HCV
6/28/16 The U.S. Food and Drug Administration recently approved Gilead’s EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg), the first oral single tablet regimen for the treatment of adults with genotypes 1-6 chronic hepatitis C virus (HCV) infection. Continue reading now.
US Bioservices is Dispensing TETRABENAZINE, generic therapy for Huntington’s chorea
3/31/16 Through a partnership with Kadmon Pharmaceuticals, LLC, and Camber Pharmceuticals, Inc., US Bioservices is now dispensing TETRABENAZINE. This generic version of XENAZINE®, which launched February 11, 2016, provides a lower-cost alternative to treat chorea (involuntary movements) associated with Huntington’s disease (HD). Continue reading now.
US Bioservices Now Dispensing MS Treatments, PLEGRIDY® and TECFIDERA®
2/8/16 We are pleased to announce that US Bioservices now has access to Biogen’s limited distribution medications, PLEGRIDY® (peginterferon beta-1a) and TECFIDERA® (dimethyl fumarate). Both drugs are used to treat people with relapsing forms of multiple sclerosis (MS). Continue reading now.
US Bioservices Dispensing Newly Approved ALECENSA®
1/30/16 The U.S. Food and Drug Administration recently approved Genentech's ALECENSA® (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lunch cancer (NSCLC) whose disease has worsened. Continue reading now.
US Bioservices Expands Access of MyPathpoint Portal to Health Insurers
4/6/15 National specialty pharmacy provider US Bioservices, a part of AmerisourceBergen, is now offering case managers working for health insurers access toMyPathpoint, a secure HIPAA-compliant web portal that delivers real-time access to patient information. The system is one of the first of its kind to offer case managers real-time access to patients’ specialty pharmacy records in an effort to ensure better experiences and outcomes for members through enhanced care coordination.Continue reading now.